EA
SRPT icon

Evolution Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Evolution Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+14
New +$265 ﹤0.01% 805

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Evolution Advisers's SRPT Position: Q2 2026 in Review

Evolution Advisers opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 14 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #805 among its holdings.

321 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Evolution Advisers held 14 shares of Sarepta Therapeutics worth $0 as of Q2 2026.
  • Sarepta Therapeutics was a new Evolution Advisers position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #805 holding.
  • 321 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.